News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “T-Cell Immunotherapy for Cancer - Pipeline Analysis”, the increasing number of investments in the T-cell immunotherapy landscape has majorly driven the global market.
 
Citing the potential of T-cell immunotherapy, various venture capitalist firms are proving funds to the companies for developing their products. This industry is benefitted by several partnerships, mergers, and acquisition with the aim to gain complementary technologies and also for commercialization. Acquisitions, collaborations and joint ventures are building up in the global T-cell immunotherapy market to fuel further development.
 
Also, numerous remarkable results in early clinical trials have driven significant investment in T-cell immunotherapy therapies, both by large biopharmaceutical companies and startup biotech firms backed by venture capital. Moreover, Government bodies have also shown support with increase in funding initiatives for the new emerging technologies. Also, several government foundations are doing extensive research in T-cell For instance, in April 2016, US Vice President and the Obama administration have taken a US$ 1 Billion initiative for a 'cancer moonshot'  to develop cancer immunotherapy treatments. Also, Former New York Mayor with a team pledged US$ 125 Million to create a new immuno-oncology focused cancer institute at Johns Hopkins.
 
Furthermore, some of the major players are also engaged in raising IPOs for funding. For instance, in June 2015, Celyad SA raised an IPO of worth US$ 100 Million. In addition to this, in May 2015, Adaptimmune raised US$ 175 Million through IPO.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM850.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm